Market Place
Sourcing Support
MSN Laboratories` Generic Trabectedin Receives Approval in the U.S.
02 Oct 2023 //
FDA
Spain`s PharmaMar posts 58% drop in 9-mth profit despite higher revenues
28 Oct 2021 //
REUTERS
PharmaMar signs a licensing agreement with RPharm to commercialize Yondelis®
24 Dec 2020 //
PRESS RELEASE
STADA and PharmaMar sign agreement to commercialize Yondelis®
17 Nov 2020 //
ZAWYA
PharmaMar signs a new agreement with Onko to commercialize Yondelis® in Turkey
10 Aug 2020 //
PRESS RELEASE
Authorised uses of cancer medicine Yondelis unchanged following review
24 Jul 2020 //
EMA
Authorised uses of cancer medicine Yondelis unchanged review of new data
24 Jul 2020 //
EMA
PharmaMar and Key Oncologics have signed an. exclusive agreement Yondelis®
19 May 2020 //
PHARMAMAR
PharmaMar has presented results of its antitumor compounds trabectedin
19 Nov 2019 //
BIOSPACE
STA To Market Sarcoma Drug In Australia, New Zealand And SE Asia
14 Oct 2019 //
BIOSPACE
The Importance of Diversity in Clinical Trials (Because Right Now, It`s Lacking)
09 Oct 2018 //
BIOSPACE
PharmaMar Will Commercialize PM1183 With the Trade Name of Zepsyre™
16 Jun 2016 //
PR NEWSWIRE
NICE ovarian cancer guideline recommends two drugs, but rejects three
25 Nov 2015 //
PHARMATIMES
Soft tissue sarcoma drug approved in Japan
29 Sep 2015 //
BIOSPECTRUM ASIA
U.S. FDA Grants Priority Review for YONDELIS
03 Feb 2015 //
PR NEWSWIRE
Speedy US Review for J&J Sarcoma Drug Yondelis
03 Feb 2015 //
PHARMA TIMES
NICE Reviews Five Ovarian Cancer Drugs
23 Dec 2014 //
PHARMA TIMES
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.